New eczema drug shows promise in Mid-Stage trial
Symptom relief
Ongoing
This study tests a new drug called ATI-045 in 110 adults with moderate-to-severe atopic dermatitis (eczema). Half receive the drug, half receive a placebo, and neither the patients nor doctors know who gets which. The main goal is to see if ATI-045 reduces eczema severity and itc…
Phase: PHASE2 • Sponsor: Aclaris Therapeutics, Inc. • Aim: Symptom relief
Last updated May 04, 2026 16:31 UTC